Mark Jones, MD
Radiation Oncology · Louisville, KYNPI 1851386767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novartis at 24.3% of the total. Reporting peaked in 2024 at $714 and has fallen 78.2% since, to $156 in 2025.
Across 51 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$229
- AstraZeneca$72
- Merck$70
- Johnson & Johnson$64
- E.r. Squibb & Sons, L.L.C.$49
- Agios Pharmaceuticals, Inc.$43
- plus $413 from 18 others
What the payments were for
- Food & beverage$940100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $229 |
| AstraZeneca(2 entities) | 3 | $72 |
| Merck | 4 | $70 |
| Johnson & Johnson | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Agios Pharmaceuticals, Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| AbbVie | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Incyte Corporation | 1 | $23 |
| Novocure Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $15 |
| Secura Bio, Inc. | 1 | $15 |
| Advanced Accelerator Applications | 1 | $13 |
How this compares
$940 in reported general payments places this provider in the 55th percentile of 81 radiation oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 76 | $465 |
| Pilocarpine Hcl | 13 | $312 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $87 |
| Fluconazole | 13 | $74 |
| Prednisone | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Louisville
- Neal DunlapLouisville$98K
- Craig SilvermanLouisville$9K
- Shiao WooLouisville$7K
- Justin AndersonLouisville$5K
- Aaron SpaldingLouisville$5K
- Yong ChaLouisville$4K
- Adrianna MastersLouisville$4K
- Alden KlarerLouisville$3K
- Carole ScharfLouisville$2K
- Phylicia OdumeLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.